Pfizer kidney cancer drug fails as initial treatment
(Reuters) - Pfizer Inc said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse.
The trial was testing the drug Inlyta in patients who have received no prior treatments and compared its effects with another kidney cancer drug, sorafenib. Inlyta is already approved to treat kidney cancer that has not responded to prior therapy.
Sorafenib is marketed as Nexavar by Onyx Pharmaceuticals Inc and Germany's Bayer AG. (Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)
- Ukraine says Russian tanks flatten town; EU to threaten more sanctions |
- F-16s dispatched for unresponsive pilot of small plane near D.C.
- EU wields Russia sanctions threat but timing vague |
- Trapped peacekeepers at Golan Heights moved to secure area: Philippine military chief
- Polish president warns Germany of Putin's 'empire' ambitions